Antiviral efficacy of nine nucleoside reverse transcriptase inhibitors against feline immunodeficiency virus in feline peripheral blood mononuclear cells

American Journal of Veterinary Research

Volumn 75, Issue 3, 2014, Pages 273-281

  Schwartz, Anita M ^a   McCrackin, Mary Ann ^a,e,f   Schinazi, Raymond F ^b   Hill, Peter B ^c,g   Vahlenkamp, Thomas W ^d,h   Tompkins, Mary B ^d   Hartmann, Katrin ^a,i  

^a UNIVERSITY OF GEORGIA   (United States)

^b EMORY UNIVERSITY   (United States)

^c UNIVERSITY OF BRISTOL   (United Kingdom)

^d NORTH CAROLINA STATE UNIVERSITY   (United States)

^e RALPH H JOHNSON VA MEDICAL CENTER   (United States)

^f MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^g UNIVERSITY OF ADELAIDE   (Australia)

^h UNIVERSITY OF LEIPZIG   (Germany)

ⁱ UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; AMDOXOVIR; DIDANOSINE; ELVUCITABINE; EMTRICITABINE; LAMIVUDINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; ZIDOVUDINE;

ANIMAL CELL; ANTIVIRAL SUSCEPTIBILITY; ARTICLE; CAT; CELL CULTURE; CONTROLLED STUDY; CYTOTOXICITY; CYTOTOXICITY ASSAY; DOSE RESPONSE; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; FELINE ACQUIRED IMMUNODEFICIENCY SYNDROME; FELINE IMMUNODEFICIENCY VIRUS; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL;

ANIMALS; ANTIVIRAL AGENTS; CATS; CELL LINE; IMMUNODEFICIENCY VIRUS, FELINE; LEUKOCYTES, MONONUCLEAR; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 84896740109     PISSN: 00029645     EISSN: 19435681     Source Type: Journal    
DOI: 10.2460/ajvr.75.3.273     Document Type: Article

References (42)

1. Pedersen NC, Ho EW, Brown ML, et al. Isolation of a T-lymphotropic virus from domestic cats with an immunodeficiency-like syndrome. Science 1987;235:790-793.
2. Bandecchi P, Matteucci D, Baldinotti F, et al. Prevalence of feline immunodeficiency virus and other retroviral infections in sick cats in Italy. Vet Immunol Immunopathol 1992;31:337-345.
3. Ishida T, Washizu T, Toriyabe K, et al. Feline immunodeficiency virus infection in cats of Japan. J Am Vet Med Assoc 1989;194:221-225.
4. Pedersen NC, Yamamoto JK, Ishida T, et al. Feline immunodeficiency virus infection. Vet Immunol Immunopathol 1989;21:111-129.
5. Zhu Y, Antony JM, Martinez JA, et al. Didanosine causes sensory neuropathy in an HIV/AIDS animal model: impaired mitochondrial and neurotrophic factor gene expression. Brain 2007;130:2011-2023.
6. Zhu YQ, Remington KM, North TW. Mutants of feline immunodeficiency virus resistant to 2′,3′-dideoxy-2′,3′-didehydrothymidine. Antimicrob Agents Chemother 1996;40:1983-1987.
7. de Mari K, Maynard L, Sanquer A, et al. Therapeutic effects of recombinant feline interferon-omega on feline leukemia virus (FeLV)-infected and FeLV/feline immunodeficiency virus (FIV)-coinfected symptomatic cats. J Vet Intern Med 2004;18:477-482.
8. Elder JH, Sundstrom M, de Rozieres S, et al. Molecular mechanisms of FIV infection. Vet Immunol Immunopathol 2008;123:3-13.
9. Gobert JM, Remington KM, Zhu YQ, et al. Multiple-drug-resistant mutants of feline immunodeficiency virus selected with 2′,3′-dideoxyinosine alone and in combination with 3'-azido-3'-deoxythymidine. Antimicrob Agents Chemother 1994;38:861-864.
10. Hernandez-Santiago BI, Mathew JS, Rapp KL, et al. Antiviral and cellular metabolism interactions between dexelvucitabine and lamivudine. Antimicrob Agents Chemother 2007;51:2130-2135.
11. Palmisano L, Vella S. A brief history of antiretroviral therapy of HIV infection: success and challenges. Ann Ist Super Sanita 2011;47:44-48.
12. Bisset LR, Lutz H, Boni J, et al. Combined effect of zidovudine (ZDV), lamivudine (3TC) and abacavir (ABC) antiretroviral therapy in suppressing in vitro FIV replication. Antiviral Res 2002;53:35-45.
13. Norelli S, El Daker S, D'Ostilio D, et al. Response of feline immunodeficiency virus (FIV) to tipranavir may provide new clues for development of broad-based inhibitors of retroviral proteases acting on drug-resistant HIV-1. Curr HIV Res 2008;6:306-317.
14. Auwerx J, Esnouf R, De Clercq E, et al. Susceptibility of feline immunodeficiency virus/human immunodeficiency virus type 1 reverse transcriptase chimeras to non-nucleoside RT inhibitors. Mol Pharmacol 2004;65:244-251.
15. Remington KM, Chesebro B, Wehrly K, et al. Mutants of feline immunodeficiency virus resistant to 3'-azido-3'-deoxythymidine. J Virol 1991;65:308-312.
16. McCrackin Stevenson MA, McBroom DG. In vitro characterization of FIV-pPPR, a pathogenic molecular clone of feline immunodeficiency virus, and two drug-resistant pol gene mutants. Am J Vet Res 2001;62:588-594.
17. Zhang W, Mauldin JK, Schmiedt CW, et al. Pharmacokinetics of zidovudine in cats. Am J Vet Res 2004;65:835-840.
18. Smyth NR, Bennett M, Gaskell RM, et al. Effect of 3'azido-2′,3′-deoxythymidine (AZT) on experimental feline immunodeficiency virus infection in domestic cats. Res Vet Sci 1994;57:220-224.
19. Hartmann K, Donath A, Beer B, et al. Use of two virustatica (AZT, PMEA) in the treatment of FIV and of FeLV seropositive cats with clinical symptoms. Vet Immunol Immunopathol 1992;35:167-175.
20. Levy J, Crawford C, Hartmann K, et al. 2008 American Association of Feline Practitioners' feline retrovirus management guidelines. J Feline Med Surg 2008;10:300-316.
21. Arai M, Earl DD, Yamamoto JK. Is AZT/3TC therapy effective against FIV infection or immunopathogenesis? Vet Immunol Immunopathol 2002;85:189-204.
22. Hartmann K, Donath A, Kraft W. AZT in the treatment of feline immunodeficiency virus infection. Part 2. Feline Pract 1995;23(6):13-20.
23. Smith RA, Remington KM, Preston BD, et al. A novel point mutation at position 156 of reverse transcriptase from feline immunodeficiency virus confers resistance to the combination of (-)-beta-2′,3′-dideoxy-3'-thiacytidine and 3'-azido-3'-deoxythymidine. J Virol 1998;72:2335-2340.
24. Larder BA, Darby G, Richman DD. HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. Science 1989;243:1731-1734.
25. Larder BA, Kemp SD. Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT). Science 1989;246:1155-1158.
26. Martins AN, Medeiros SO, Simonetti JP, et al. Phylogenetic and genetic analysis of feline immunodeficiency virus gag, pol, and env genes from domestic cats undergoing nucleoside reverse transcriptase inhibitor treatment or treatment-naive cats in Rio de Janeiro, Brazil. J Virol 2008;82:7863-7874.
27. Phillips TR, Talbott RL, Lamont C, et al. Comparison of two host cell range variants of feline immunodeficiency virus. J Virol 1990;64:4605-4613.
28. Lerner DL, Grant CK, de Parseval A, et al. FIV infection of IL-2-dependent and-independent feline lymphocyte lines: host cells range distinctions and specific cytokine upregulation. Vet Immunol Immunopathol 1998;65:277-297.
29. Joshi A, Vahlenkamp TW, Garg H, et al. Preferential replication of FIV in activated CD4(+)CD25(+)T cells independent of cellular proliferation. Virology 2004;321:307-322.
30. Hubert JJ. Spearman-Karber method. In: Hubert JJ, ed. Bioassay. 2nd ed. Dubuque, Iowa: Hunt Publishing Co, 1984;65-66.
31. Smyth NR, McCracken C, Gaskell RM, et al. Susceptibility in cell culture of feline immunodeficiency virus to eighteen antiviral agents. J Antimicrob Chemother 1994;34:589-594.
32. Hartmann K, Donath A, Kraft W. AZT in the treatment of feline immunodeficiency virus infection. Part 1. Feline Pract 1995;23(5):16-21.
33. Vahlenkamp TW, De Ronde A, Balzarini J, et al. (R)-9-(2-phosphonylmethoxypropyl)-2,6-diaminopurine is a potent inhibitor of feline immunodeficiency virus infection. Antimicrob Agents Chemother 1995;39:746-749.
34. Balzarini J, Egberink H, Hartmann K, et al. Antiretrovirus specificity and intracellular metabolism of 2′,3′-didehydro-2′,3′-dideoxythymidine (stavudine) and its 5'-monophosphate triesterprodrug So324. Mol Pharmacol 1996;50:1207-1213.
35. Du DL, Volpe DA, Grieshaber CK, et al. In vitro myelotoxicity of 2′,3′-dideoxynucleosides on human hematopoietic progenitor cells. Exp Hematol 1990;18:832-836.
36. Lambert JS, Seidlin M, Reichman RC, et al. 2′,3′-dideoxyinosine (ddI) in patients with the acquired immunodeficiency syndrome or AIDS-related complex. A phase I trial. N Engl J Med 1990;322:1333-1340.
37. White AJ. Mitochondrial toxicity and HIV therapy. Sex Transm Infect 2001;77:158-173.
38. van der Meer FJ, Schuurman NM, Balzarini J, et al. Comparative evaluation of the activity of antivirals towards feline immunodeficiency virus in different cell culture systems. Antiviral Res 2007;76:198-201.
39. North TW, North GL, Pedersen NC. Feline immunodeficiency virus, a model for reverse transcriptase-targeted chemotherapy for acquired immune deficiency syndrome. Antimicrob Agents Chemother 1989;33:915-919.
40. Hart S, Nolte I. Long-term treatment of diseased, FIV-seropositive field cats with azidothymidine (AZT). Zentralbl Veterinarmed A 1995;42:397-409.
41. Zhu Y, Vergote D, Pardo C, et al. CXCR3 activation by lentivirus infection suppresses neuronal autophagy: neuroprotective effects of antiretroviral therapy. FASEB J 2009;23:2928-2941.
42. Delta Coordinating Committee. Evidence for prolonged clinical benefit from initial combination antiretroviral therapy: Delta extended follow-up. HIV Med 2001;2:181-188.